The MiningNewsWire Podcast

Personalized treatment for advanced breast cancer is a massive global medical need. According to latest figures from the Centers for Disease Control, in the United States alone more than 41,000 women die from breast cancer each year. Hope is on the horizon, however, as innovative biomedical companies apply their research and technologies to bring personalized immunotherapies to market for this unmet medical need. Among these companies is BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), an immune-oncology-focused biotech company developing the first off-the-shelf personalized immunotherapy for advanced breast cancer. The company’s technology is based on a targeted immunotherapy regime that has seen encouraging results in clinical trials. Other biotechs in the personalized cancer immunotherapy space include Gilead Sciences, Inc. (NASDAQ: GILD), the parent company of Kite Pharma; Cellectis S.A. (NASDAQ: CLLS); Neon Therapeutics, Inc. (NASDAQ: NTGN); and Loxo Oncology, Inc. (NASDAQ: LOXO).